FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
- 1 October 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 12 (10), 1247-1252
- https://doi.org/10.1634/theoncologist.12-10-1247
Abstract
Learning Objectives: After completing this course, the reader will be able to: Add vorinostat to the armamentarium of drugs for CTCL.Identify the mechanism of action of vorinostat.Identify goals of therapy of CTCL.Identify active CTCL therapies.Identify CTCL response criteria. Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.comKeywords
This publication has 16 references indexed in Scilit:
- Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid MalignanciesClinical Cancer Research, 2007
- Discovery and development of SAHA as an anticancer agentOncogene, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic MalignanciesJournal of Clinical Oncology, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- Epigenetic therapy of cancer: past, present and futureNature Reviews Drug Discovery, 2006
- Selective Induction of Apoptosis by Histone Deacetylase Inhibitor SAHA in Cutaneous T-Cell Lymphoma Cells: Relevance to Mechanism of Therapeutic ActionJournal of Investigative Dermatology, 2005
- Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistanceBlood, 2004
- Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case reportBlood, 2001